OrderlyMeds review: November 2026 prices, terms and what to verify
As of November 20, 2026, OrderlyMeds’s own page lists $299 tirzepatide and $149 semaglutide a month ("Same Price, Every Month"); new customers can get two months for $299 or $149. On this site’s computed price-and-transparency score it has 27.9 of 40 points, position 6 of 27 compounded programs.
Released · Last reviewed · how we verify
What OrderlyMeds charges now
OrderlyMeds’s prices were read on its own page on November 20, 2026. This site compares programs on the all-in month-to-month price at the maintenance dose, which counts any required membership or program fee and leaves out first-month offers. A 28-day billing cycle means 13 charges a year, not 12.
| Medication | Month to month, all-in | Billing basis | Lowest printed rate | Year at month-to-month price | Read |
|---|---|---|---|---|---|
| Compounded tirzepatide | $299 | per month | $149 (2-month new-customer offer, $299) | $3,588 (12 months) | 2026-11-20 |
| Compounded semaglutide | $149 | per month | $74 (2-month new-customer offer, $149) | $1,788 (12 months) | 2026-11-20 |
OrderlyMeds on the computed score
On this site’s computed price-and-transparency score it has 27.9 of 40 points, position 6 of 27 compounded programs. The score covers the two parts of our seven-category methodology that can be checked for every program on the same day: pricing transparency (20 points) and total annual cost (20 points). The full ranking is on the rankings page.
| Check | Tirzepatide | Semaglutide |
|---|---|---|
| prints a month-to-month price | yes (+4) | yes (+4) |
| medication and care in one price | yes (+4) | yes (+4) |
| same price at every dose | yes (+4) | yes (+4) |
| no membership fee | yes (+4) | yes (+4) |
| price read on its own page on November 20, 2026 | yes (+4) | yes (+4) |
| Year at the month-to-month price | $3,588 | $1,788 |
| Total annual cost points | 5.7 of 20 | 10.1 of 20 |
| Score for this drug | 25.7 of 40 | 30.1 of 40 |
FDA warning letters
FDA’s warning-letter index lists warning letter 728291 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to OrderlyMeds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does OrderlyMeds charge a membership fee?
No required membership fee appeared on OrderlyMeds’s page when it was read on November 20, 2026; the figures above are the full recurring charge before tax.
Does OrderlyMeds take insurance?
Not for compounded medication. OrderlyMeds is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does OrderlyMeds serve?
OrderlyMeds’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- OrderlyMeds pricing page (read November 20, 2026)
- FDA warning letter 728291 to OrderlyMeds (dated 2026-06-08, posted 2026-06-16; read November 20, 2026)